Forecast

There is no analyst data available for this company.

News Go to news feed

Stratec gains 35% in three months and secures products under five-year contracts

Stratec, a developer and manufacturer of automation and diagnostic systems for in-vitro diagnostics, recorded a share-price gain of about 35% over the past three months. Management stresses that products are contractually secured for the next five years, meaning growth through 2030 is more firmly underpinned than current figures show. The focus is on the long-term outlook beyond 2026. » More on finanzen.net
STRATEC SE: Supervisory board member Ralf Leistner receives 29,556 shares as a gift

Ralf Leistner, member of the supervisory board of STRATEC SE, received a total of 29,556 shares of the company on 19 August 2026. The shares were transferred to him free of charge by Hermann Leistner and Doris Leistner as a gift. The transaction took place outside a trading venue and was published in accordance with reporting obligations. » More on de.investing.com
Stratec raises margins and cash flow despite revenue decline in H1 2026

Stratec reports H1 2026 revenue of €112.5m (-5.1%) with adjusted EBIT of €7.7m. The adjusted EBIT margin rose sharply to 11.9% in Q2 (Q1: 5.4%) and free cash flow improved to €23.5m versus -€14.7m a year earlier. Management confirmed the full-year outlook with an expected adjusted EBIT margin of around 10% and sees the business as year-end weighted; risks remain from supply chain bottlenecks and weak demand for consumables. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, STRATEC has already paid 0,60€ in dividends. The last payout was in June.

Financials

In the last quarter, STRATEC had revenue of 59.11m€ and net profit of 4.16m€

(EUR)	Jun 2026	YoY
Revenue	+59.11m	0,31%
Gross profit	+15.24m	4,62%
Net profit	+4.16m	219,91%
EBITDA	+8.52m	14,11%

Fundamentals

Metric	Value
Market capitalization	+272.89m€
Number of shares	12.16m
52-week high/low	+70,20€ - +22,45€
Dividend yield	+2,66%
Dividends TTM	+0,60€
Beta	0,8
P/E ratio	−558,75
PEG ratio	+8,58
P/B ratio	+1,14
P/S ratio	+1,11

Company profile

Die Stratec SE entwickelt und produziert zusammen mit ihren Tochtergesellschaften Automatisierungs- und Instrumentierungslösungen in den Bereichen In-vitro-Diagnostik und Life Sciences in Deutschland, der Europäischen Union und international. Das Unternehmen ist in drei Segmenten tätig: Instrumentation, Diatron und Smart Consumables. Das Segment Instrumentation entwickelt und fertigt automatisierte Analysesysteme, einschließlich Serviceteile und Verbrauchsmaterialien für Kunden aus der klinischen Diagnostik und Biotechnologie. Das Segment Diatron bietet Systeme, Systemkomponenten, Verbrauchsmaterialien und Tests für die Hämatologie und die klinische Chemie mit geringem Durchsatz an. Das Segment Smart Consumables entwickelt und fertigt intelligente Verbrauchsmaterialien für die Bereiche Diagnostik, Biowissenschaften und Medizintechnik. Das Unternehmen war früher als STRATEC Biomedical AG bekannt und änderte im Dezember 2018 seinen Namen in Stratec SE. Die Stratec SE wurde 1979 gegründet und hat ihren Hauptsitz in Birkenfeld, Deutschland.

Name	STRATEC
CEO	Marcus Wolfinger
Headquarters	Birkenfeld, rp Germany
Website	stratec.com
Sector	Health Care
Industry	Health Care Technology
IPO	06/16/2000
Employees	1.403